Yoan Hurtado, PhD candidate and Seerave Bioinformatics Fellow and a researcher affiliated with the Elkrief/Routy immuno-oncology group at the CRCHUM. He holds a Master's in Bioinformatics with a specialization in In Silico Drug Design from Université Paris Cité and has worked at Gustave Roussy on clinical, metabolomic, and metagenomic data in immuno-oncology. He is a co-author on recent papers linking the gut microbiome to immunotherapy response, including Birebent et al. (Oncoimmunology, 2025) on surrogate markers of intestinal dysfunction as predictors of survival in advanced cancers, and Mallard de La Varende et al. (Cancer Cell, 2026) on subclinical cholestasis driving gut dysbiosis and immunotherapy resistance.